Teva Targets Biological Cause of Celiac Disease

Teva Pharmaceutical Industries (TEVA)'s brand-name-free candidate TEV-53408 is a long-acting monoclonal antibody that inhibits interleukin-15 (IL-15). In a randomized placebo-controlled Phase 2a trial involving 50 adults, a single subcutaneous dose showed a significant improvement in villus height to crypt depth ratio at week 8 of -0.43 compared to -0.88 in the placebo group, with a treatment difference of 0.45, 95% confidence interval 0.06–0.84, and a p-value less than 0.05. Intraepithelial lymphocyte increase was also suppressed at 0.37 versus 27.60 in the placebo group, with no new safety signals observed. The ability to directly reduce histological damage in celiac disease, where current standard treatment is a strict gluten-free diet, represents a clinical differentiator.

A Single Antibody Targets Multiple Immune Diseases

TEV-53408 is under development for celiac disease in Phase 2a and vitiligo in Phase 1b, with Teva also advancing a Phase 2b trial for vitiligo. The FDA granted Fast Track designation to the celiac disease program in May 2025. Competing candidates include the gluten-degrading enzyme latiglutenase and TAK-101, which modulates the gluten immune response, but no celiac disease drugs are yet approved. If subsequent trials demonstrate that histological effects translate into symptom improvement and durability, Teva's pipeline-in-a-product strategy could convert into tangible asset value.

BioMarin Monetizes Revenue from Competitive Products

BioMarin Pharmaceutical (BMRN) and Ascendis Pharma (ASND) resolved their global licensing dispute over the C-type natriuretic peptide (CNP) patent. Ascendis' Yuviwel (navepegritide, a CNP analog prodrug) is a once-weekly treatment for achondroplasia granted FDA accelerated approval on February 27, 2026. BioMarin's approved and marketed product Voxzogo (vosoritide, an NPR-B agonist) is administered daily. Ascendis will pay 20% of U.S. net sales and 18% of EU, Brazil, and South Korea net sales until May 2030, with U.S. royalties retroactive from the first commercial sale. Given Voxzogo's 2025 sales of $927 million, the agreement partially offsets revenue erosion from the competitive product through royalty payments.

mRNA Platforms Show Divergent Outcomes

GSK (GSK) plans to initiate Phase 3 trials in September 2026 for FLUm3HA.b-3NA after Phase 2 results in 971 participants showed higher immune responses than standard and high-dose influenza vaccines. The FDA granted Fast Track designation in July 2026, with competitors including Moderna (MRNA)'s mFlusiva (mRNA-1010.6, an HA antigen mRNA vaccine) approved by the FDA in August 2026 and existing vaccines Fluzone and Fluarix. In contrast, BioNTech (BNTX) and Roche (ROG)'s personalized neoantigen mRNA vaccine autogene cevumeran (BNT122/RO7198457) was discontinued in a colorectal cancer Phase 2 trial due to imbalanced overall survival and limited efficacy. While late-stage development competition in influenza intensifies, the oncology mRNA field highlights the importance of patient selection and combination strategies. Annual influenza infections affect approximately 1 billion cases, while the termination of the BioNTech-Roche trial raises R&D standards for personalized mRNA therapies, which require checkpoint inhibitor combinations and precise patient selection over monotherapy adjuvants.